IMPT Plan Optimization via Internal Organ Deformation Modeling

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Intensity modulated proton therapy (IMPT) plans fail to account for internal organ movement and deformation, leading to inaccuracies in dose distribution due to positional changes, which are not adequately addressed by existing robust optimization techniques that primarily focus on setup and range uncertainties.

Innovation Solution

A method and system that generate a nominal dose distribution, setup error dose distribution, and internal organ dose distribution, optimizing the IMPT plan by minimizing a total objective value that includes these components, and controlling a proton therapy apparatus to deliver the optimized plan, which accounts for internal organ movement and deformation through image warping and deformation vector fields.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If robust optimization is used to account for setup and range uncertainties, then the IMPT plan becomes more robust to positioning errors, but it fails to account for internal organ movement and deformation

Engineering Contradiction:
Improverobustness to positioning errorsVSAvoidinternal organ movement and deformation information
Core Design Contradiction:
ReliabilityVSLoss of information

Solution Approach 1:

The patent applies preliminary action by generating deformation vector fields and warped images before dose calculation to predict and compensate for internal organ movement and deformation. This pre-processing step creates corrected anatomical representations that account for anticipated organ changes, allowing the optimization to proactively address these uncertainties rather than reacting to them during treatment delivery.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent introduces deformation vector fields and warped images as intermediary elements between the original anatomical data and the dose calculation. These intermediaries transform the raw imaging data into corrected representations that incorporate predicted organ movement, serving as a bridge that translates anatomical uncertainty into a format usable for robust optimization without requiring direct real-time organ tracking.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Manufacturing precision

If internal organ movement and deformation are incorporated into IMPT planning, then dose distribution accuracy improves, but computational complexity increases

Engineering Contradiction:
Improvedose distribution accuracyVSAvoidcomputational complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent segments the complexity management by separating the handling of different uncertainty types into distinct computational modules: setup error modeling, range uncertainty modeling, and internal organ deformation modeling. Each module processes specific aspects independently, allowing the system to manage complex calculations through modular organization rather than monolithic processing.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent applies partial action by selectively applying deformation corrections only to regions containing internal organs that exhibit significant movement or deformation, rather than uniformly processing the entire anatomical volume. This targeted approach reduces unnecessary computational effort while maintaining dose accuracy in critical areas where organ movement affects treatment outcomes.

Inventive Principle:
Principle #16Partial or excessive action

Data Source

PatentEP3393582B1Intensity modulated proton therapy (IMPT) plan optimization based at least on internal organ anticipated movement and/or expected deformation
Publication Date: 2022.10.26 KONINKLIJKE PHILIPS NV
  • EP3393582B1 patent drawingFigure 1
  • EP3393582B1 patent drawingFigure 2
  • EP3393582B1 patent drawingFigure 3~6

AI summary

A method includes generating a nominal dose distribution based on an image and clinical goals. The method further includes generating a setup error dose distribution based on range and setup uncertainties. The method further includes generating a dose distribution for a parameter of an internal organ. The method further includes optimizing a planned dose distribution of an intensity modulated proton therapy plan by minimizing a total objective value including the nominal dose distribution, the setup error dose distribution dose distribution,and the dose distribution for the internal organ. The method further includes generating a final dose distribution for the intensity modulated proton therapy plan based on beam parameters of the optimized planned dose distribution. The method further includes controlling a proton therapy apparatus configured to deliver proton therapy based on the intensity modulated proton therapy plan with the optimized planned dose distribution.